Searchable abstracts of presentations at key conferences in endocrinology

ea0081p152 | Pituitary and Neuroendocrinology | ECE2022

Up to one third of the children with attention deficit with hyperactivity disorder (ADHD) may have an isolated and increased free-T3 level

Caci Herve , Caron Philippe

Introduction: Thyroid hormones are involved in the development of the fœtus and the child, and abnormal thyroid function is expected to play a role in neurodevelopmental disorders such as Attention Deficit with Hyperactivity Disorder (ADHD). The high prevalence of ADHD in patients with resistance to thyroid hormone syndrome is well documented but, surprisingly, the reported literature showed ambiguous results mostly suggesting that the thyroid function tests are normal in...

ea0022p752 | Thyroid | ECE2010

Results from an observational study on general practitioners' and endocrinologists' medical practice for the management of simple goiter in France

Philippe Caron , Frederic Landron

The primary objective of this observational study was to determine the medical practice for the management of simple goiter in France from a representative sample of general practitioners (GPs) and endocrinologists (ENDOs). As secondary objective, this study reported the incidence rate of simple goiter, toxic and non-toxic nodular goiters in France.Four hundred and sixty-nine general practitioners and 195 endocrinologists participated in the study. Eight...

ea0084ps1-01-01 | COVID & Thyroid Disease | ETA2022

Autoimmune and inflammatory thyroid diseases following SARS-CoV-2 vaccines: an update from a systematic review of the literature

Grunenwald Solange , Caron Philippe

Since the emergence of the Covid-19 pandemic in 2019, a massive vaccination campaign has been undertaken around the world, and SARS-CoV-2 vaccines-induced thyroid diseases became more frequently described in the literature. Subacute thyroiditis is reported in 52 patients, mean age 45.5±1.8 years, mainly in women (n = 39), after the first (62%) or the second (38%) dose of mRNA (60%), inactivated whole-virus (25%) and adenoviral-vectored (13.5%) vaccines. The mean ti...

ea0056oc1.1 | Benign thyroid diseases | ECE2018

Familial gestational hyperthyroidism caused by Val597ile mutant of TSH receptor gene with human chorionic gonadotropin hypersensitivity

Caron Philippe , Susini Marion , Savagner Frederique

Context: Familial gestational hyperthyroidism caused by mutations of TSH receptor gene, hypersensitive to hCG, is rare. Only two mutations at the same amino acid (lys183Arg, Lys183Asn) in the leucine-rich region of the extracellular N-terminal domain of the TSH receptor have been reported.Patients: A 38-year-old woman was seen during the first trimester of her second pregnancy for weight loss (5 kgs), nausea and vomiting. Thyroid function test revealed t...

ea0081p136 | Environmental Endocrinology | ECE2022

Orbital inflammatory disease following mrna sars-cov-2 vaccine: a case report

Solange Grunenwald , Lethellier Gabriel , Imbert Philippe , Dekeister Celine , Caron Philippe

SARS-CoV-2 vaccination campaigns document a satisfactory high profile of protection against Covid-19 infection, but auto-immune/inflammatory diseases have been reported following Covid-19 vaccines. A 65-year-old woman reported two days following her first dose of the BNT162b2 mRNA vaccine tearing, eye irritation, conjunctival redness, peri-orbital swelling, spontaneous hematoma of the right lower eyelid, right greater than left proptosis, with a spontaneous improvement of symp...

ea0063p247 | Pituitary and Neuroendocrinology 1 | ECE2019

MRI follow-up is not useful in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogs (SMSa)

Grandgeorge Naia , Barchetti Giovanni , Grunenwald Solange , Bonneville Fabrice , Caron Philippe

Introduction: Primary SMSa treatment can be associated with hormonal remission and tumor shrinkage in patients with GH-secreting pituitary adenomas. In the 2014 Endocrine Society guideline for Acromegaly, there is no specific mention of MRI follow-up during long-term SMSa treatment. The aim of this study was to evaluate any change of GH-secreting adenoma size during primary SMSa treatment and whether regular MRI follow-up was necessary in acromegalic patients treated with firs...

ea0063p338 | Thyroid 1 | ECE2019

Thyroid-associated orbitopathy and quality of life: correlation of GO-QoL with clinical activity score and severity in 101 patients

Borel Marine , Grunenwald Solange , Imbert Philippe , Dekeister Celine , Caron Philippe

Thyroid-associated orbitopathy (TAO) is a classic and sometimes severe complication of autoimmune process associated with thyroid diseases, more common in Graves’ disease. Due to its functional impairment and disfiguring clinical presentation, TAO affects the quality of life of patients. Few studies have examined the importance of this impact in these patients. The main objective of this retrospective study is to determine if there is a correlation between the deteriorati...

ea0035p910 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Relationship between early and longer-term tumour volume reduction (TVR) with primary lanreotide Autogel (LAN-ATG) therapy in treatment-naive acromegalic patients: post hoc analyses of the PRIMARYS study

Caron Philippe , Maisonobe Pascal , Thanh Xuan-Mai Truong , Bevan John

Introduction: PRIMARYS provided evidence for TVR with monthly LAN-ATG 120 mg in treatment-naïve acromegalic patients (63% achieved TVR ≥20% with a favourable safety profile). To help clinicians with therapeutic management of acromegaly, tumour responsive over time needs to be further explored.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patients with pituitary macroade...

ea0035p911 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Tumour and hormonal response with lanreotide Autogel 120 mg in treatment-naive acromegalic patients: further post hoc data from the PRIMARYS study

Bevan John , Maisonobe Pascal , Thanh Xuan-Mai Truong , Caron Philippe

Introduction: The PRIMARYS study demonstrated primary treatment with lanreotide Autogel 120 mg could achieve favourable tumour and hormone response rates in a large cohort of acromegalic patients. Here, we further interrogate the PRIMARYS database on the relationship between the tumour volume responsiveness and hormonal control.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patient...

ea0070aep759 | Pituitary and Neuroendocrinology | ECE2020

MRI follow-up of patients with acromegaly treated with first-generation somatostatin analogues (SMSa): Is there a difference during primary or post-operative treatment?

Naia Grandgeorge , Giovanni Barchetti , Solange Grunenwald , Fabrice Bonneville , Caron Philippe

Objectives: First-generation SMSa are the medical treatment of choice in the management of acromegaly, mainly as adjuvant treatment of pituitary surgery when normal IGF-1 is not obtained or as primary treatment in selected patients. The main objective of this study is to evaluate regular pituitary MRI follow-up of acromegalic patients treated with SMSa as adjuvant treatment of pituitary surgery. The secondary objective is to compare the anti-tumoral effect of SMSa in post-oper...